β-2 adrenergic receptor (AR): Another immune checkpoint (IC)' A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: 2d303775fe2382cad46cc4be5d36d84f2d98dfdd
First added on: Feb 14, 2025